Facebook Target REDUCED and 4 Must-See Stock Analyses

Facebook, Inc. (NASDAQ:FB) target has been lowered by Needham since the firm believes that the company’s monetization of mobile traffic has been slower than previously expected. The firm keeps a Buy rating on the stock as it continues to see several long-term positive catalysts for the company.

Don’t Miss: FACEBOOK: The ZUCK Finally Speaks.

Biogen Idec Inc. (NASDAQ:BIIB) price target has been increased by Credit Suisse due to its group leading EPS growth and expectations for its hemophilia franchise, which may be worth more than $1 billion. Shares have an Outperform rating.

Facebook, Inc. (NASDAQ:FB): According to JPMorgan, Facebook CEO Mark Zuckerberg was incrementally positive regarding the company’s mobile opportunity yesterday at the TechCrunch Disrupt conference. The firm still expects Facebook’s advertising revenue to re-accelerate during the second half of 2012 and believes the risk/reward on shares remain attractive at current levels. The firm maintains an Overweight rating on the stock.

Google Inc. (NASDAQ:GOOG): Bernstein thinks that Google’s revenue would be nearly 5 percent lower relative to PC search momentum if Apple (NASDAQ:AAPL) decides to replace Google as the default search engine in iOS. The firm raised its target on Google to $850 from $727 and keeps an Outperform rating on the stock.

Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS) target has been increased by RBC Capital since the firm believes that the DSMB’s decision to allow the continuing of the Phase III VALOR study for vosaroxin to move forward with the addition of 225 patients which reflects positively on the drug’s risk-benefit profile. The firm predicts that the study will generate positive data, and it keeps an Outperform rating on the stock.

Don’t Miss: How Much Will Nasdaq Pay for Facebook IPO FIASCO?

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>